Abstract
Serum levels of placental protein 10 (PP10) were measured by radioimmunoassay in patients with trophoblastic (n = 23) and non-trophoblastic (n = 122) gynaecological tumours before, during and after treatment. Elevated levels (greater than 2.0 micrograms/l) were found in 96% of patients with an untreated trophoblastic tumour, and in 22%, 20% and 12% of patients with endometrial, cervical and ovarian carcinoma, respectively. After treatment the levels fell in patients with trophoblastic disease. Although PP10 may be tumour-associated in such cases, it is premature to assume any significance for PP10 as a tumour marker in clinical practice, because changes in serum hCG levels are much more informative.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
